Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade Article Swipe
Jun Zhou
,
Kathleen M. Mahoney
,
Anita Giobbie‐Hurder
,
Fengmin Zhao
,
Charles Lee
,
Xiaoyun Liao
,
Scott J. Rodig
,
Jingjing Li
,
Xinqi Wu
,
Lisa H. Butterfield
,
Matthias Piesche
,
Michael P. Manos
,
Lauren M. Eastman
,
Glenn Dranoff
,
Gordon J. Freeman
,
F. Stephen Hodi
·
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1158/2326-6066.cir-16-0329
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1158/2326-6066.cir-16-0329
Blockade of the pathway including programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) has produced clinical benefits in patients with a variety of cancers. Elevated levels of soluble PD-L1 (sPD-L1) have been associated with worse prognosis in renal cell carcinoma and multiple myeloma. However, the regulatory roles and function of sPD-L1 particularly in connection with immune checkpoint blockade treatment are not fully understood. We identified four splice variants of PD-L1 in melanoma cells, and all of them are secreted. Secretion of sPD-L1 resulted from alternate splicing activities, cytokine induction, cell stress, cell injury, and cell death in melanoma cells. Pretreatment levels of sPD-L1 were elevated in stage IV melanoma patient sera compared with healthy donors. High pretreatment levels of sPD-L1 were associated with increased likelihood of progressive disease in patients treated by CTLA-4 or PD-1 blockade. Although changes in circulating sPD-L1 early after treatment could not distinguish responders from those with progressive disease, after five months of treatment by CTLA-4 or PD-1 blockade patients who had increased circulating sPD-L1 had greater likelihood of developing a partial response. Induction of sPD-L1 was associated with increased circulating cytokines after CTLA-4 blockade but not following PD-1 blockade. Circulating sPD-L1 is a prognostic biomarker that may predict outcomes for subgroups of patients receiving checkpoint inhibitors. Cancer Immunol Res; 5(6); 480–92. ©2017 AACR.
Related Topics
Concepts
Blockade
Immune checkpoint
Medicine
Melanoma
Cancer
PD-L1
Biomarker
Immunotherapy
Nivolumab
Immune system
Cancer research
Internal medicine
Immunology
Oncology
Receptor
Biology
Biochemistry
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1158/2326-6066.cir-16-0329
- http://cancerimmunolres.aacrjournals.org/content/canimm/5/6/480.full.pdf
- OA Status
- bronze
- Cited By
- 351
- References
- 49
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2615907969
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2615907969Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/2326-6066.cir-16-0329Digital Object Identifier
- Title
-
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint BlockadeWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2017Year of publication
- Publication date
-
2017-05-18Full publication date if available
- Authors
-
Jun Zhou, Kathleen M. Mahoney, Anita Giobbie‐Hurder, Fengmin Zhao, Charles Lee, Xiaoyun Liao, Scott J. Rodig, Jingjing Li, Xinqi Wu, Lisa H. Butterfield, Matthias Piesche, Michael P. Manos, Lauren M. Eastman, Glenn Dranoff, Gordon J. Freeman, F. Stephen HodiList of authors in order
- Landing page
-
https://doi.org/10.1158/2326-6066.cir-16-0329Publisher landing page
- PDF URL
-
https://cancerimmunolres.aacrjournals.org/content/canimm/5/6/480.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://cancerimmunolres.aacrjournals.org/content/canimm/5/6/480.full.pdfDirect OA link when available
- Concepts
-
Blockade, Immune checkpoint, Medicine, Melanoma, Cancer, PD-L1, Biomarker, Immunotherapy, Nivolumab, Immune system, Cancer research, Internal medicine, Immunology, Oncology, Receptor, Biology, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
351Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 16, 2024: 42, 2023: 43, 2022: 45, 2021: 66Per-year citation counts (last 5 years)
- References (count)
-
49Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2615907969 |
|---|---|
| doi | https://doi.org/10.1158/2326-6066.cir-16-0329 |
| ids.doi | https://doi.org/10.1158/2326-6066.cir-16-0329 |
| ids.mag | 2615907969 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/28522460 |
| ids.openalex | https://openalex.org/W2615907969 |
| fwci | 19.82711189 |
| mesh[0].qualifier_ui | Q000627 |
| mesh[0].descriptor_ui | D061067 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | therapeutic use |
| mesh[0].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D000074322 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D000971 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[3].qualifier_ui | Q000037 |
| mesh[3].descriptor_ui | D060890 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | antagonists & inhibitors |
| mesh[3].descriptor_name | B7-H1 Antigen |
| mesh[4].qualifier_ui | Q000097 |
| mesh[4].descriptor_ui | D060890 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | blood |
| mesh[4].descriptor_name | B7-H1 Antigen |
| mesh[5].qualifier_ui | Q000235 |
| mesh[5].descriptor_ui | D060890 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | genetics |
| mesh[5].descriptor_name | B7-H1 Antigen |
| mesh[6].qualifier_ui | Q000378 |
| mesh[6].descriptor_ui | D060890 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | metabolism |
| mesh[6].descriptor_name | B7-H1 Antigen |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D000068258 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Bevacizumab |
| mesh[8].qualifier_ui | Q000097 |
| mesh[8].descriptor_ui | D014408 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | blood |
| mesh[8].descriptor_name | Biomarkers, Tumor |
| mesh[9].qualifier_ui | Q000235 |
| mesh[9].descriptor_ui | D014408 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | genetics |
| mesh[9].descriptor_name | Biomarkers, Tumor |
| mesh[10].qualifier_ui | Q000378 |
| mesh[10].descriptor_ui | D014408 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | metabolism |
| mesh[10].descriptor_name | Biomarkers, Tumor |
| mesh[11].qualifier_ui | Q000037 |
| mesh[11].descriptor_ui | D060908 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | antagonists & inhibitors |
| mesh[11].descriptor_name | CTLA-4 Antigen |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D045744 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Cell Line, Tumor |
| mesh[13].qualifier_ui | Q000097 |
| mesh[13].descriptor_ui | D016207 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | blood |
| mesh[13].descriptor_name | Cytokines |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D006801 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Humans |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D000074324 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Ipilimumab |
| mesh[16].qualifier_ui | Q000097 |
| mesh[16].descriptor_ui | D008545 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | blood |
| mesh[16].descriptor_name | Melanoma |
| mesh[17].qualifier_ui | Q000188 |
| mesh[17].descriptor_ui | D008545 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | drug therapy |
| mesh[17].descriptor_name | Melanoma |
| mesh[18].qualifier_ui | Q000235 |
| mesh[18].descriptor_ui | D008545 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | genetics |
| mesh[18].descriptor_name | Melanoma |
| mesh[19].qualifier_ui | Q000378 |
| mesh[19].descriptor_ui | D008545 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | metabolism |
| mesh[19].descriptor_name | Melanoma |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D020033 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Protein Isoforms |
| mesh[21].qualifier_ui | Q000627 |
| mesh[21].descriptor_ui | D061067 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | therapeutic use |
| mesh[21].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D000074322 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[23].qualifier_ui | Q000627 |
| mesh[23].descriptor_ui | D000971 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | therapeutic use |
| mesh[23].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[24].qualifier_ui | Q000037 |
| mesh[24].descriptor_ui | D060890 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | antagonists & inhibitors |
| mesh[24].descriptor_name | B7-H1 Antigen |
| mesh[25].qualifier_ui | Q000097 |
| mesh[25].descriptor_ui | D060890 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | blood |
| mesh[25].descriptor_name | B7-H1 Antigen |
| mesh[26].qualifier_ui | Q000235 |
| mesh[26].descriptor_ui | D060890 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | genetics |
| mesh[26].descriptor_name | B7-H1 Antigen |
| mesh[27].qualifier_ui | Q000378 |
| mesh[27].descriptor_ui | D060890 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | metabolism |
| mesh[27].descriptor_name | B7-H1 Antigen |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D000068258 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Bevacizumab |
| mesh[29].qualifier_ui | Q000097 |
| mesh[29].descriptor_ui | D014408 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | blood |
| mesh[29].descriptor_name | Biomarkers, Tumor |
| mesh[30].qualifier_ui | Q000235 |
| mesh[30].descriptor_ui | D014408 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | genetics |
| mesh[30].descriptor_name | Biomarkers, Tumor |
| mesh[31].qualifier_ui | Q000378 |
| mesh[31].descriptor_ui | D014408 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | metabolism |
| mesh[31].descriptor_name | Biomarkers, Tumor |
| mesh[32].qualifier_ui | Q000037 |
| mesh[32].descriptor_ui | D060908 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | antagonists & inhibitors |
| mesh[32].descriptor_name | CTLA-4 Antigen |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D045744 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Cell Line, Tumor |
| mesh[34].qualifier_ui | Q000097 |
| mesh[34].descriptor_ui | D016207 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | blood |
| mesh[34].descriptor_name | Cytokines |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D006801 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Humans |
| mesh[36].qualifier_ui | Q000627 |
| mesh[36].descriptor_ui | D000074324 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | therapeutic use |
| mesh[36].descriptor_name | Ipilimumab |
| mesh[37].qualifier_ui | Q000097 |
| mesh[37].descriptor_ui | D008545 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | blood |
| mesh[37].descriptor_name | Melanoma |
| mesh[38].qualifier_ui | Q000188 |
| mesh[38].descriptor_ui | D008545 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | drug therapy |
| mesh[38].descriptor_name | Melanoma |
| mesh[39].qualifier_ui | Q000235 |
| mesh[39].descriptor_ui | D008545 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | genetics |
| mesh[39].descriptor_name | Melanoma |
| mesh[40].qualifier_ui | Q000378 |
| mesh[40].descriptor_ui | D008545 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | metabolism |
| mesh[40].descriptor_name | Melanoma |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D020033 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Protein Isoforms |
| type | article |
| title | Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade |
| biblio.issue | 6 |
| biblio.volume | 5 |
| biblio.last_page | 492 |
| biblio.first_page | 480 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T10580 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9991000294685364 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immunotherapy and Immune Responses |
| topics[2].id | https://openalex.org/T11020 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9973000288009644 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Immune Cell Function and Interaction |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2778468042 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8645597696304321 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q273976 |
| concepts[0].display_name | Blockade |
| concepts[1].id | https://openalex.org/C2780851360 |
| concepts[1].level | 4 |
| concepts[1].score | 0.729840874671936 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q21686041 |
| concepts[1].display_name | Immune checkpoint |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7194421291351318 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2777658100 |
| concepts[3].level | 2 |
| concepts[3].score | 0.655116081237793 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q180614 |
| concepts[3].display_name | Melanoma |
| concepts[4].id | https://openalex.org/C121608353 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5678741335868835 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[4].display_name | Cancer |
| concepts[5].id | https://openalex.org/C2781053074 |
| concepts[5].level | 4 |
| concepts[5].score | 0.5453547835350037 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q21100639 |
| concepts[5].display_name | PD-L1 |
| concepts[6].id | https://openalex.org/C2781197716 |
| concepts[6].level | 2 |
| concepts[6].score | 0.47779494524002075 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q864574 |
| concepts[6].display_name | Biomarker |
| concepts[7].id | https://openalex.org/C2777701055 |
| concepts[7].level | 3 |
| concepts[7].score | 0.470528244972229 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[7].display_name | Immunotherapy |
| concepts[8].id | https://openalex.org/C2780030458 |
| concepts[8].level | 4 |
| concepts[8].score | 0.46650025248527527 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7041828 |
| concepts[8].display_name | Nivolumab |
| concepts[9].id | https://openalex.org/C8891405 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4261896014213562 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[9].display_name | Immune system |
| concepts[10].id | https://openalex.org/C502942594 |
| concepts[10].level | 1 |
| concepts[10].score | 0.4091186821460724 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[10].display_name | Cancer research |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.39994028210639954 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| concepts[12].id | https://openalex.org/C203014093 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3680933117866516 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[12].display_name | Immunology |
| concepts[13].id | https://openalex.org/C143998085 |
| concepts[13].level | 1 |
| concepts[13].score | 0.3666267395019531 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[13].display_name | Oncology |
| concepts[14].id | https://openalex.org/C170493617 |
| concepts[14].level | 2 |
| concepts[14].score | 0.29323625564575195 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[14].display_name | Receptor |
| concepts[15].id | https://openalex.org/C86803240 |
| concepts[15].level | 0 |
| concepts[15].score | 0.1345078945159912 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[15].display_name | Biology |
| concepts[16].id | https://openalex.org/C55493867 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[16].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/blockade |
| keywords[0].score | 0.8645597696304321 |
| keywords[0].display_name | Blockade |
| keywords[1].id | https://openalex.org/keywords/immune-checkpoint |
| keywords[1].score | 0.729840874671936 |
| keywords[1].display_name | Immune checkpoint |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7194421291351318 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/melanoma |
| keywords[3].score | 0.655116081237793 |
| keywords[3].display_name | Melanoma |
| keywords[4].id | https://openalex.org/keywords/cancer |
| keywords[4].score | 0.5678741335868835 |
| keywords[4].display_name | Cancer |
| keywords[5].id | https://openalex.org/keywords/pd-l1 |
| keywords[5].score | 0.5453547835350037 |
| keywords[5].display_name | PD-L1 |
| keywords[6].id | https://openalex.org/keywords/biomarker |
| keywords[6].score | 0.47779494524002075 |
| keywords[6].display_name | Biomarker |
| keywords[7].id | https://openalex.org/keywords/immunotherapy |
| keywords[7].score | 0.470528244972229 |
| keywords[7].display_name | Immunotherapy |
| keywords[8].id | https://openalex.org/keywords/nivolumab |
| keywords[8].score | 0.46650025248527527 |
| keywords[8].display_name | Nivolumab |
| keywords[9].id | https://openalex.org/keywords/immune-system |
| keywords[9].score | 0.4261896014213562 |
| keywords[9].display_name | Immune system |
| keywords[10].id | https://openalex.org/keywords/cancer-research |
| keywords[10].score | 0.4091186821460724 |
| keywords[10].display_name | Cancer research |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.39994028210639954 |
| keywords[11].display_name | Internal medicine |
| keywords[12].id | https://openalex.org/keywords/immunology |
| keywords[12].score | 0.3680933117866516 |
| keywords[12].display_name | Immunology |
| keywords[13].id | https://openalex.org/keywords/oncology |
| keywords[13].score | 0.3666267395019531 |
| keywords[13].display_name | Oncology |
| keywords[14].id | https://openalex.org/keywords/receptor |
| keywords[14].score | 0.29323625564575195 |
| keywords[14].display_name | Receptor |
| keywords[15].id | https://openalex.org/keywords/biology |
| keywords[15].score | 0.1345078945159912 |
| keywords[15].display_name | Biology |
| language | en |
| locations[0].id | doi:10.1158/2326-6066.cir-16-0329 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2765010658 |
| locations[0].source.issn | 2326-6066, 2326-6074 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 2326-6066 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Cancer Immunology Research |
| locations[0].source.host_organization | https://openalex.org/P4310320273 |
| locations[0].source.host_organization_name | American Association for Cancer Research |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320273 |
| locations[0].source.host_organization_lineage_names | American Association for Cancer Research |
| locations[0].license | |
| locations[0].pdf_url | http://cancerimmunolres.aacrjournals.org/content/canimm/5/6/480.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cancer Immunology Research |
| locations[0].landing_page_url | https://doi.org/10.1158/2326-6066.cir-16-0329 |
| locations[1].id | pmid:28522460 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cancer immunology research |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/28522460 |
| locations[2].id | pmh:oai:europepmc.org:4930127 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | http://europepmc.org/pmc/articles/PMC5642913 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:5642913 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Cancer Immunol Res |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/5642913 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5060655774 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3163-0887 |
| authorships[0].author.display_name | Jun Zhou |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[0].affiliations[0].raw_affiliation_string | 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[0].affiliations[1].raw_affiliation_string | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[0].affiliations[2].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[0].affiliations[2].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[0].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[0].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[0].institutions[1].id | https://openalex.org/I136199984 |
| authorships[0].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | Harvard University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Jun Zhou |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[1].author.id | https://openalex.org/A5038736877 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-3869-6803 |
| authorships[1].author.display_name | Kathleen M. Mahoney |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1316535847 |
| authorships[1].affiliations[0].raw_affiliation_string | 4Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[1].affiliations[1].raw_affiliation_string | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[1].institutions[0].id | https://openalex.org/I1316535847 |
| authorships[1].institutions[0].ror | https://ror.org/04drvxt59 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1316535847 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Beth Israel Deaconess Medical Center |
| authorships[1].institutions[1].id | https://openalex.org/I4210117453 |
| authorships[1].institutions[1].ror | https://ror.org/02jzgtq86 |
| authorships[1].institutions[1].type | facility |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210117453 |
| authorships[1].institutions[1].country_code | US |
| authorships[1].institutions[1].display_name | Dana-Farber Cancer Institute |
| authorships[1].institutions[2].id | https://openalex.org/I136199984 |
| authorships[1].institutions[2].ror | https://ror.org/03vek6s52 |
| authorships[1].institutions[2].type | education |
| authorships[1].institutions[2].lineage | https://openalex.org/I136199984 |
| authorships[1].institutions[2].country_code | US |
| authorships[1].institutions[2].display_name | Harvard University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kathleen M. Mahoney |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 4Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. |
| authorships[2].author.id | https://openalex.org/A5071788399 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-2496-7737 |
| authorships[2].author.display_name | Anita Giobbie‐Hurder |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[2].affiliations[0].raw_affiliation_string | 5Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[2].affiliations[1].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[2].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[2].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[2].institutions[1].id | https://openalex.org/I136199984 |
| authorships[2].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | Harvard University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Anita Giobbie-Hurder |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 5Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
| authorships[3].author.id | https://openalex.org/A5038425269 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-9826-3703 |
| authorships[3].author.display_name | Fengmin Zhao |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[3].affiliations[0].raw_affiliation_string | 5Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
| authorships[3].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[3].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Fengmin Zhao |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | 5Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
| authorships[4].author.id | https://openalex.org/A5100716198 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-7317-6662 |
| authorships[4].author.display_name | Charles Lee |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[4].affiliations[0].raw_affiliation_string | 5Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
| authorships[4].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[4].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sandra Lee |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | 5Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
| authorships[5].author.id | https://openalex.org/A5079359304 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-6709-1520 |
| authorships[5].author.display_name | Xiaoyun Liao |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[5].affiliations[0].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I1283280774 |
| authorships[5].affiliations[1].raw_affiliation_string | 6Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. |
| authorships[5].institutions[0].id | https://openalex.org/I1283280774 |
| authorships[5].institutions[0].ror | https://ror.org/04b6nzv94 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I1283280774, https://openalex.org/I48633490 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Brigham and Women's Hospital |
| authorships[5].institutions[1].id | https://openalex.org/I4210117453 |
| authorships[5].institutions[1].ror | https://ror.org/02jzgtq86 |
| authorships[5].institutions[1].type | facility |
| authorships[5].institutions[1].lineage | https://openalex.org/I4210117453 |
| authorships[5].institutions[1].country_code | US |
| authorships[5].institutions[1].display_name | Dana-Farber Cancer Institute |
| authorships[5].institutions[2].id | https://openalex.org/I136199984 |
| authorships[5].institutions[2].ror | https://ror.org/03vek6s52 |
| authorships[5].institutions[2].type | education |
| authorships[5].institutions[2].lineage | https://openalex.org/I136199984 |
| authorships[5].institutions[2].country_code | US |
| authorships[5].institutions[2].display_name | Harvard University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Xiaoyun Liao |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 6Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. |
| authorships[6].author.id | https://openalex.org/A5058975989 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-1761-9769 |
| authorships[6].author.display_name | Scott J. Rodig |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[6].affiliations[0].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I1283280774 |
| authorships[6].affiliations[1].raw_affiliation_string | 6Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. |
| authorships[6].institutions[0].id | https://openalex.org/I1283280774 |
| authorships[6].institutions[0].ror | https://ror.org/04b6nzv94 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I1283280774, https://openalex.org/I48633490 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Brigham and Women's Hospital |
| authorships[6].institutions[1].id | https://openalex.org/I4210117453 |
| authorships[6].institutions[1].ror | https://ror.org/02jzgtq86 |
| authorships[6].institutions[1].type | facility |
| authorships[6].institutions[1].lineage | https://openalex.org/I4210117453 |
| authorships[6].institutions[1].country_code | US |
| authorships[6].institutions[1].display_name | Dana-Farber Cancer Institute |
| authorships[6].institutions[2].id | https://openalex.org/I136199984 |
| authorships[6].institutions[2].ror | https://ror.org/03vek6s52 |
| authorships[6].institutions[2].type | education |
| authorships[6].institutions[2].lineage | https://openalex.org/I136199984 |
| authorships[6].institutions[2].country_code | US |
| authorships[6].institutions[2].display_name | Harvard University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Scott Rodig |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 6Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. |
| authorships[7].author.id | https://openalex.org/A5100635922 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-7664-887X |
| authorships[7].author.display_name | Jingjing Li |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[7].affiliations[0].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[7].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[7].affiliations[1].raw_affiliation_string | 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[7].affiliations[2].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[7].affiliations[2].raw_affiliation_string | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[7].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[7].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[7].institutions[0].type | facility |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[7].institutions[1].id | https://openalex.org/I136199984 |
| authorships[7].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[7].institutions[1].country_code | US |
| authorships[7].institutions[1].display_name | Harvard University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Jingjing Li |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[8].author.id | https://openalex.org/A5103093153 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-4979-4596 |
| authorships[8].author.display_name | Xinqi Wu |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[8].affiliations[0].raw_affiliation_string | 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[8].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[8].affiliations[1].raw_affiliation_string | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[8].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[8].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[8].institutions[0].type | facility |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[8].institutions[1].id | https://openalex.org/I136199984 |
| authorships[8].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[8].institutions[1].country_code | US |
| authorships[8].institutions[1].display_name | Harvard University |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Xinqi Wu |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[9].author.id | https://openalex.org/A5026029856 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-3439-9844 |
| authorships[9].author.display_name | Lisa H. Butterfield |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210128526 |
| authorships[9].affiliations[0].raw_affiliation_string | 8Immunologic Monitoring and Cellular Products Laboratory, Hillman Cancer Center Research Pavilion, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. |
| authorships[9].affiliations[1].institution_ids | https://openalex.org/I170201317 |
| authorships[9].affiliations[1].raw_affiliation_string | 7Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. |
| authorships[9].institutions[0].id | https://openalex.org/I4210128526 |
| authorships[9].institutions[0].ror | https://ror.org/03bw34a45 |
| authorships[9].institutions[0].type | facility |
| authorships[9].institutions[0].lineage | https://openalex.org/I170201317, https://openalex.org/I4210128526 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | UPMC Hillman Cancer Center |
| authorships[9].institutions[1].id | https://openalex.org/I170201317 |
| authorships[9].institutions[1].ror | https://ror.org/01an3r305 |
| authorships[9].institutions[1].type | education |
| authorships[9].institutions[1].lineage | https://openalex.org/I170201317 |
| authorships[9].institutions[1].country_code | US |
| authorships[9].institutions[1].display_name | University of Pittsburgh |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Lisa H. Butterfield |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | 7Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania., 8Immunologic Monitoring and Cellular Products Laboratory, Hillman Cancer Center Research Pavilion, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. |
| authorships[10].author.id | https://openalex.org/A5032855671 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-9050-1946 |
| authorships[10].author.display_name | Matthias Piesche |
| authorships[10].countries | CL, US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2799535320 |
| authorships[10].affiliations[0].raw_affiliation_string | 9Biomedical Research Laboratories, Medicine Faculty, Catholic University of Maule, Talca, Chile. |
| authorships[10].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[10].affiliations[1].raw_affiliation_string | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[10].institutions[0].id | https://openalex.org/I2799535320 |
| authorships[10].institutions[0].ror | https://ror.org/04vdpck27 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I2799535320 |
| authorships[10].institutions[0].country_code | CL |
| authorships[10].institutions[0].display_name | Catholic University of the Maule |
| authorships[10].institutions[1].id | https://openalex.org/I4210117453 |
| authorships[10].institutions[1].ror | https://ror.org/02jzgtq86 |
| authorships[10].institutions[1].type | facility |
| authorships[10].institutions[1].lineage | https://openalex.org/I4210117453 |
| authorships[10].institutions[1].country_code | US |
| authorships[10].institutions[1].display_name | Dana-Farber Cancer Institute |
| authorships[10].institutions[2].id | https://openalex.org/I136199984 |
| authorships[10].institutions[2].ror | https://ror.org/03vek6s52 |
| authorships[10].institutions[2].type | education |
| authorships[10].institutions[2].lineage | https://openalex.org/I136199984 |
| authorships[10].institutions[2].country_code | US |
| authorships[10].institutions[2].display_name | Harvard University |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Matthias Piesche |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 9Biomedical Research Laboratories, Medicine Faculty, Catholic University of Maule, Talca, Chile. |
| authorships[11].author.id | https://openalex.org/A5070590609 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-0841-207X |
| authorships[11].author.display_name | Michael P. Manos |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[11].affiliations[0].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[11].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[11].affiliations[1].raw_affiliation_string | 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[11].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[11].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[11].institutions[0].type | facility |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[11].institutions[1].id | https://openalex.org/I136199984 |
| authorships[11].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[11].institutions[1].type | education |
| authorships[11].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[11].institutions[1].country_code | US |
| authorships[11].institutions[1].display_name | Harvard University |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Michael P. Manos |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[12].author.id | https://openalex.org/A5088118544 |
| authorships[12].author.orcid | https://orcid.org/0009-0009-5757-843X |
| authorships[12].author.display_name | Lauren M. Eastman |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[12].affiliations[0].raw_affiliation_string | 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[12].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[12].affiliations[1].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[12].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[12].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[12].institutions[0].type | facility |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[12].institutions[1].id | https://openalex.org/I136199984 |
| authorships[12].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[12].institutions[1].type | education |
| authorships[12].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[12].institutions[1].country_code | US |
| authorships[12].institutions[1].display_name | Harvard University |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Lauren M. Eastman |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[13].author.id | https://openalex.org/A5028608171 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-2341-7517 |
| authorships[13].author.display_name | Glenn Dranoff |
| authorships[13].affiliations[0].raw_affiliation_string | 10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts. |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Glenn Dranoff |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | 10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts. |
| authorships[14].author.id | https://openalex.org/A5075310347 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-7210-5616 |
| authorships[14].author.display_name | Gordon J. Freeman |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[14].affiliations[0].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[14].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[14].affiliations[1].raw_affiliation_string | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[14].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[14].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[14].institutions[0].type | facility |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[14].institutions[1].id | https://openalex.org/I136199984 |
| authorships[14].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[14].institutions[1].type | education |
| authorships[14].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[14].institutions[1].country_code | US |
| authorships[14].institutions[1].display_name | Harvard University |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Gordon J. Freeman |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[15].author.id | https://openalex.org/A5084967339 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-6825-091X |
| authorships[15].author.display_name | F. Stephen Hodi |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[15].affiliations[0].raw_affiliation_string | 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[15].affiliations[1].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[15].affiliations[1].raw_affiliation_string | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[15].affiliations[2].institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| authorships[15].affiliations[2].raw_affiliation_string | 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| authorships[15].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[15].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[15].institutions[0].type | facility |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[15].institutions[1].id | https://openalex.org/I136199984 |
| authorships[15].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[15].institutions[1].type | education |
| authorships[15].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[15].institutions[1].country_code | US |
| authorships[15].institutions[1].display_name | Harvard University |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | F. Stephen Hodi |
| authorships[15].is_corresponding | True |
| authorships[15].raw_affiliation_strings | 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 2Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., 3Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | http://cancerimmunolres.aacrjournals.org/content/canimm/5/6/480.full.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-23T05:10:03.516525 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W3007246459, https://openalex.org/W4393219064, https://openalex.org/W2263980547, https://openalex.org/W2085972006, https://openalex.org/W4361271945, https://openalex.org/W2794408630, https://openalex.org/W3197188017, https://openalex.org/W2153718647, https://openalex.org/W2921651111, https://openalex.org/W3204147903 |
| cited_by_count | 351 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 16 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 42 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 43 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 45 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 66 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 66 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 36 |
| counts_by_year[7].year | 2018 |
| counts_by_year[7].cited_by_count | 27 |
| counts_by_year[8].year | 2017 |
| counts_by_year[8].cited_by_count | 10 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1158/2326-6066.cir-16-0329 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2765010658 |
| best_oa_location.source.issn | 2326-6066, 2326-6074 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 2326-6066 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Cancer Immunology Research |
| best_oa_location.source.host_organization | https://openalex.org/P4310320273 |
| best_oa_location.source.host_organization_name | American Association for Cancer Research |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320273 |
| best_oa_location.source.host_organization_lineage_names | American Association for Cancer Research |
| best_oa_location.license | |
| best_oa_location.pdf_url | http://cancerimmunolres.aacrjournals.org/content/canimm/5/6/480.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cancer Immunology Research |
| best_oa_location.landing_page_url | https://doi.org/10.1158/2326-6066.cir-16-0329 |
| primary_location.id | doi:10.1158/2326-6066.cir-16-0329 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2765010658 |
| primary_location.source.issn | 2326-6066, 2326-6074 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 2326-6066 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Cancer Immunology Research |
| primary_location.source.host_organization | https://openalex.org/P4310320273 |
| primary_location.source.host_organization_name | American Association for Cancer Research |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320273 |
| primary_location.source.host_organization_lineage_names | American Association for Cancer Research |
| primary_location.license | |
| primary_location.pdf_url | http://cancerimmunolres.aacrjournals.org/content/canimm/5/6/480.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cancer Immunology Research |
| primary_location.landing_page_url | https://doi.org/10.1158/2326-6066.cir-16-0329 |
| publication_date | 2017-05-18 |
| publication_year | 2017 |
| referenced_works | https://openalex.org/W2155464214, https://openalex.org/W1489480103, https://openalex.org/W2417401725, https://openalex.org/W4230861071, https://openalex.org/W2035660473, https://openalex.org/W2136313650, https://openalex.org/W2050999762, https://openalex.org/W2036905020, https://openalex.org/W2029086221, https://openalex.org/W2147240268, https://openalex.org/W2129806226, https://openalex.org/W2115918781, https://openalex.org/W2010121426, https://openalex.org/W2160834915, https://openalex.org/W2125616358, https://openalex.org/W1971208896, https://openalex.org/W2124427232, https://openalex.org/W2267145540, https://openalex.org/W2145758395, https://openalex.org/W2073125824, https://openalex.org/W2088763423, https://openalex.org/W2042318018, https://openalex.org/W2121820529, https://openalex.org/W2038325530, https://openalex.org/W2009719437, https://openalex.org/W2005253163, https://openalex.org/W2043058822, https://openalex.org/W2133075384, https://openalex.org/W2166662937, https://openalex.org/W2128012941, https://openalex.org/W2044074212, https://openalex.org/W2033635529, https://openalex.org/W2100600402, https://openalex.org/W1871669466, https://openalex.org/W2155045799, https://openalex.org/W2117692326, https://openalex.org/W2048657818, https://openalex.org/W1965037168, https://openalex.org/W6716781117, https://openalex.org/W2016983859, https://openalex.org/W2103383530, https://openalex.org/W2040793402, https://openalex.org/W2086437355, https://openalex.org/W2136731993, https://openalex.org/W2039123767, https://openalex.org/W2053353274, https://openalex.org/W2344221521, https://openalex.org/W2163804741, https://openalex.org/W2791808262 |
| referenced_works_count | 49 |
| abstract_inverted_index.1 | 8, 17 |
| abstract_inverted_index.a | 26, 180, 203 |
| abstract_inverted_index.IV | 113 |
| abstract_inverted_index.We | 69 |
| abstract_inverted_index.by | 137, 164 |
| abstract_inverted_index.in | 23, 42, 58, 76, 102, 111, 134, 144 |
| abstract_inverted_index.is | 202 |
| abstract_inverted_index.of | 2, 28, 32, 55, 74, 81, 86, 107, 124, 131, 162, 178, 184, 212 |
| abstract_inverted_index.or | 139, 166 |
| abstract_inverted_index.all | 80 |
| abstract_inverted_index.and | 10, 46, 53, 79, 99 |
| abstract_inverted_index.are | 65, 83 |
| abstract_inverted_index.but | 195 |
| abstract_inverted_index.for | 210 |
| abstract_inverted_index.had | 171, 175 |
| abstract_inverted_index.has | 19 |
| abstract_inverted_index.its | 11 |
| abstract_inverted_index.may | 207 |
| abstract_inverted_index.not | 66, 151, 196 |
| abstract_inverted_index.the | 3, 50 |
| abstract_inverted_index.was | 186 |
| abstract_inverted_index.who | 170 |
| abstract_inverted_index.High | 121 |
| abstract_inverted_index.PD-1 | 140, 167, 198 |
| abstract_inverted_index.Res; | 219 |
| abstract_inverted_index.been | 37 |
| abstract_inverted_index.cell | 14, 44, 95, 97, 100 |
| abstract_inverted_index.five | 160 |
| abstract_inverted_index.four | 71 |
| abstract_inverted_index.from | 89, 154 |
| abstract_inverted_index.have | 36 |
| abstract_inverted_index.sera | 116 |
| abstract_inverted_index.that | 206 |
| abstract_inverted_index.them | 82 |
| abstract_inverted_index.were | 109, 126 |
| abstract_inverted_index.with | 25, 39, 60, 118, 128, 156, 188 |
| abstract_inverted_index.5(6); | 220 |
| abstract_inverted_index.AACR. | 223 |
| abstract_inverted_index.PD-L1 | 34, 75 |
| abstract_inverted_index.after | 148, 159, 192 |
| abstract_inverted_index.could | 150 |
| abstract_inverted_index.death | 15, 101 |
| abstract_inverted_index.early | 147 |
| abstract_inverted_index.fully | 67 |
| abstract_inverted_index.renal | 43 |
| abstract_inverted_index.roles | 52 |
| abstract_inverted_index.stage | 112 |
| abstract_inverted_index.those | 155 |
| abstract_inverted_index.worse | 40 |
| abstract_inverted_index.(PD-1) | 18 |
| abstract_inverted_index.CTLA-4 | 138, 165, 193 |
| abstract_inverted_index.Cancer | 217 |
| abstract_inverted_index.cells, | 78 |
| abstract_inverted_index.cells. | 104 |
| abstract_inverted_index.immune | 61 |
| abstract_inverted_index.levels | 31, 106, 123 |
| abstract_inverted_index.months | 161 |
| abstract_inverted_index.sPD-L1 | 56, 87, 108, 125, 146, 174, 185, 201 |
| abstract_inverted_index.splice | 72 |
| abstract_inverted_index.©2017 | 222 |
| abstract_inverted_index.(PD-L1) | 9 |
| abstract_inverted_index.Immunol | 218 |
| abstract_inverted_index.changes | 143 |
| abstract_inverted_index.disease | 133 |
| abstract_inverted_index.donors. | 120 |
| abstract_inverted_index.greater | 176 |
| abstract_inverted_index.healthy | 119 |
| abstract_inverted_index.injury, | 98 |
| abstract_inverted_index.partial | 181 |
| abstract_inverted_index.pathway | 4 |
| abstract_inverted_index.patient | 115 |
| abstract_inverted_index.predict | 208 |
| abstract_inverted_index.protein | 16 |
| abstract_inverted_index.soluble | 33 |
| abstract_inverted_index.stress, | 96 |
| abstract_inverted_index.treated | 136 |
| abstract_inverted_index.variety | 27 |
| abstract_inverted_index.(sPD-L1) | 35 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Although | 142 |
| abstract_inverted_index.Blockade | 1 |
| abstract_inverted_index.Elevated | 30 |
| abstract_inverted_index.However, | 49 |
| abstract_inverted_index.benefits | 22 |
| abstract_inverted_index.blockade | 63, 168, 194 |
| abstract_inverted_index.cancers. | 29 |
| abstract_inverted_index.clinical | 21 |
| abstract_inverted_index.compared | 117 |
| abstract_inverted_index.cytokine | 93 |
| abstract_inverted_index.disease, | 158 |
| abstract_inverted_index.elevated | 110 |
| abstract_inverted_index.function | 54 |
| abstract_inverted_index.melanoma | 77, 103, 114 |
| abstract_inverted_index.multiple | 47 |
| abstract_inverted_index.myeloma. | 48 |
| abstract_inverted_index.outcomes | 209 |
| abstract_inverted_index.patients | 24, 135, 169, 213 |
| abstract_inverted_index.produced | 20 |
| abstract_inverted_index.receptor | 12 |
| abstract_inverted_index.resulted | 88 |
| abstract_inverted_index.splicing | 91 |
| abstract_inverted_index.variants | 73 |
| abstract_inverted_index.480–92. | 221 |
| abstract_inverted_index.Induction | 183 |
| abstract_inverted_index.Secretion | 85 |
| abstract_inverted_index.alternate | 90 |
| abstract_inverted_index.biomarker | 205 |
| abstract_inverted_index.blockade. | 141, 199 |
| abstract_inverted_index.carcinoma | 45 |
| abstract_inverted_index.cytokines | 191 |
| abstract_inverted_index.following | 197 |
| abstract_inverted_index.including | 5 |
| abstract_inverted_index.increased | 129, 172, 189 |
| abstract_inverted_index.prognosis | 41 |
| abstract_inverted_index.receiving | 214 |
| abstract_inverted_index.response. | 182 |
| abstract_inverted_index.secreted. | 84 |
| abstract_inverted_index.subgroups | 211 |
| abstract_inverted_index.treatment | 64, 149, 163 |
| abstract_inverted_index.associated | 38, 127, 187 |
| abstract_inverted_index.checkpoint | 62, 215 |
| abstract_inverted_index.connection | 59 |
| abstract_inverted_index.developing | 179 |
| abstract_inverted_index.identified | 70 |
| abstract_inverted_index.induction, | 94 |
| abstract_inverted_index.likelihood | 130, 177 |
| abstract_inverted_index.prognostic | 204 |
| abstract_inverted_index.programmed | 6, 13 |
| abstract_inverted_index.regulatory | 51 |
| abstract_inverted_index.responders | 153 |
| abstract_inverted_index.Circulating | 200 |
| abstract_inverted_index.activities, | 92 |
| abstract_inverted_index.circulating | 145, 173, 190 |
| abstract_inverted_index.distinguish | 152 |
| abstract_inverted_index.inhibitors. | 216 |
| abstract_inverted_index.progressive | 132, 157 |
| abstract_inverted_index.understood. | 68 |
| abstract_inverted_index.Pretreatment | 105 |
| abstract_inverted_index.death-ligand | 7 |
| abstract_inverted_index.particularly | 57 |
| abstract_inverted_index.pretreatment | 122 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 99 |
| corresponding_author_ids | https://openalex.org/A5084967339 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 16 |
| corresponding_institution_ids | https://openalex.org/I136199984, https://openalex.org/I4210117453 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8700000047683716 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.99422244 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |